Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03763136Phase 1Completed

Treating Heart Failure With hPSC-CMs

Role: lead

NCT06866600Phase 1Not Yet Recruiting

IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure

Role: lead

NCT05566600Early Phase 1Unknown

Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

Role: lead

NCT05223894Phase 1Unknown

Treating Heart Failure With hiPSC-CMs

Role: lead

NCT04982081Phase 1Unknown

Treating Congestive HF With hiPSC-CMs Through Endocardial Injection

Role: lead

All 5 trials loaded